专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060287324A1 Bicyclic heterocycles as cannabinoid-1 receptor modulators 有权
标题翻译：双环杂环作为大麻素-1受体调节剂
公开(公告)号：US20060287324A1
公开(公告)日：2006-12-21
申请号：US11455039
申请日：2006-06-16
申请人： Chongqing Sun , Yanting Huang , Doree Sitkoff , Taekyu Lee , William Ewing
发明人： Chongqing Sun , Yanting Huang , Doree Sitkoff , Taekyu Lee , William Ewing
IPC分类号： A61K31/503 , A61K31/4745 , C07D487/04 , C07D471/02
CPC分类号： C07D471/04 , C07D487/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R1, R2, R3 and R8 are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法，其单独和与一种或多种另外的治疗剂。所述化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中A，B，R 1，R 2，R 3 本文描述了本文和/或 8。

2. 发明申请

US20070004772A1 Triazolopyridine cannabinoid receptor 1 antagonists 有权
标题翻译：三唑并吡啶大麻素受体1拮抗剂
公开(公告)号：US20070004772A1
公开(公告)日：2007-01-04
申请号：US11454322
申请日：2006-06-16
申请人： Chongqing Sun , Philip Sher , Gang Wu , William Ewing , Yanting Huang , Taekyu Lee , Natesan Murugesan , Richard Sulsky
发明人： Chongqing Sun , Philip Sher , Gang Wu , William Ewing , Yanting Huang , Taekyu Lee , Natesan Murugesan , Richard Sulsky
IPC分类号： C07D471/02 , A61K31/4745
CPC分类号： C07D471/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物，以及使用式I化合物单独和与一种或多种其他治疗剂。该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中R 1，R 2，R 3，本文描述了R 4和R 5。

3. 发明授权

US07632837B2 Bicyclic heterocycles as cannabinoid-1 receptor modulators 有权
标题翻译：双环杂环作为大麻素-1受体调节剂
公开(公告)号：US07632837B2
公开(公告)日：2009-12-15
申请号：US11455039
申请日：2006-06-16
申请人： Chongqing Sun , Yanting Huang , Doree F. Sitkoff , Taekyu Lee , William Ewing
发明人： Chongqing Sun , Yanting Huang , Doree F. Sitkoff , Taekyu Lee , William Ewing
IPC分类号： C07D487/04 , A61K31/5025
CPC分类号： C07D471/04 , C07D487/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R1, R2, R3 and R8 are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法，其单独和与一种或多种另外的治疗剂。该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中A，B，R 1，R 2，R 3和R 8在本文中描述。

4. 发明申请

US20100048612A1 BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS 有权
标题翻译：作为CANNABINOID-1受体调节剂的双相异构体
公开(公告)号：US20100048612A1
公开(公告)日：2010-02-25
申请号：US12609436
申请日：2009-10-30
申请人： Chongqing Sun , Yanting Huang , Doree F. Sitkoff , Taekyu Lee , William Ewing
发明人： Chongqing Sun , Yanting Huang , Doree F. Sitkoff , Taekyu Lee , William Ewing
IPC分类号： A61K31/437 , C07D471/04
CPC分类号： C07D471/04 , C07D487/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R1, R2, R3 and R8 are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法，其单独和与一种或多种另外的治疗剂。该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中A，B，R 1，R 2，R 3和R 8在本文中描述。

5. 发明授权

US07572808B2 Triazolopyridine cannabinoid receptor 1 antagonists 有权
标题翻译：三唑并吡啶大麻素受体1拮抗剂
公开(公告)号：US07572808B2
公开(公告)日：2009-08-11
申请号：US11454322
申请日：2006-06-16
申请人： Chongqing Sun , Philip M. Sher , Gang Wu , William R. Ewing , Yanting Huang , Taekyu Lee , Natesan Murugesan , Richard B. Sulsky
发明人： Chongqing Sun , Philip M. Sher , Gang Wu , William R. Ewing , Yanting Huang , Taekyu Lee , Natesan Murugesan , Richard B. Sulsky
IPC分类号： A61K31/44 , C07D471/02
CPC分类号： C07D471/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物，以及使用式I化合物单独和与一种或多种其他治疗剂。该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中本文描述了R1，R2，R3，R4和R5。

6. 发明授权

US07858639B2 Bicyclic heterocycles as cannabinoid-1 receptor modulators 有权
标题翻译：双环杂环作为大麻素-1受体调节剂
公开(公告)号：US07858639B2
公开(公告)日：2010-12-28
申请号：US12609436
申请日：2009-10-30
申请人： Chongqing Sun , Yanting Huang , Doree F. Sitkoff , Taekyu Lee , William R. Ewing
发明人： Chongqing Sun , Yanting Huang , Doree F. Sitkoff , Taekyu Lee , William R. Ewing
IPC分类号： C07D471/04 , A61K31/437
CPC分类号： C07D471/04 , C07D487/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R1, R2, R3 and R8 are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法，其单独和与一种或多种另外的治疗剂。该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中A，B，R 1，R 2，R 3和R 8在本文中描述。

7. 再颁专利

USRE39679E1 Substituted heterocycle fused gamma-carbolines 有权
公开(公告)号：USRE39679E1
公开(公告)日：2007-06-05
申请号：US11356423
申请日：2006-02-16
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
IPC分类号： C07D267/22 , C07D281/18 , C07D267/02 , C07D279/00 , C07D265/34
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

8. 发明申请

US20070049613A1 Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists 有权
标题翻译：取代的三环杂环作为血清素受体激动剂和拮抗剂
公开(公告)号：US20070049613A1
公开(公告)日：2007-03-01
申请号：US11509354
申请日：2006-08-24
申请人： Wenting Chen , Taekyu Lee
发明人： Wenting Chen , Taekyu Lee
IPC分类号： A61K31/473 , C07D221/06
CPC分类号： C07D221/16
摘要： The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I
摘要翻译：本申请描述了根据式I的化合物，包括其所有药学上可接受的盐，前药，溶剂合物和立体异构体，药物组合物，其包含至少一种根据式I的化合物和任选的至少一种另外的治疗剂以及治疗各种疾病的方法与调节血清素受体相关的病症和紊乱，例如：代谢疾病，其包括但不限于肥胖，糖尿病，糖尿病并发症，动脉粥样硬化，葡萄糖耐量异常和血脂异常; 包括但不限于焦虑，抑郁，强迫症，惊恐障碍，精神病，精神分裂症，睡眠障碍，性障碍和社交恐惧症的中枢神经系统疾病; 头痛偏头痛和使用根据式I的化合物的胃肠道疾病

9. 发明授权

US06699852B2 Substituted pyridoindoles as serotonin agonists and antagonists 有权
标题翻译：取代的吡啶并吲哚作为血清素激动剂和拮抗剂
公开(公告)号：US06699852B2
公开(公告)日：2004-03-02
申请号：US10026611
申请日：2001-12-19
申请人： Albert Robichaud , John M. Fevig , Ian S. Mitchell , Taekyu Lee , Wenting Chen , Joseph Cacciola
发明人： Albert Robichaud , John M. Fevig , Ian S. Mitchell , Taekyu Lee , Wenting Chen , Joseph Cacciola
IPC分类号： A61K3133
CPC分类号： C07D471/16 , C07D498/16 , C07D513/16
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译：本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 5，R 6，R 7，R 8，R <9>，X，b，k和n，这里描述虚线。本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症，以及胃肠道疾病如胃肠道运动功能障碍。

10. 发明授权

US06548493B1 Substituted heterocycle fused gamma-carbolines 有权
公开(公告)号：US06548493B1
公开(公告)日：2003-04-15
申请号：US09594008
申请日：2000-06-15
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. B. Calvello , David M. Zawrotny
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. B. Calvello , David M. Zawrotny
IPC分类号： C07D51316
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式